Combined Treatment of Bortezomib, Continuous Low-Dose Cyclophosphamide and Dexamethasone Followed By One Year of Maintenance Treatment for Refractory or Relapsed Multiple Myeloma Patients: A Prospective Phase II Study

硼替佐米 医学 环磷酰胺 地塞米松 多发性骨髓瘤 养生 沙利度胺 维持疗法 内科学 长春新碱 化疗 外科 肿瘤科 自体干细胞移植 胃肠病学
作者
Esther GM Waal de,Linda Munck de,Gerhard Woolthuis,Annet velden Van Der,Yvonne Tromp,Mels Hoogendoorn,Edo Vellenga,Sjoerd Hovenga
出处
期刊:Blood [Elsevier BV]
卷期号:124 (21): 4733-4733 被引量:1
标识
DOI:10.1182/blood.v124.21.4733.4733
摘要

Abstract Introduction: Combination therapy for longer periods but at low dose, also called metronomic scheduling, might be an effective manner to treat patients with relapsing myeloma. In particular if the used agents attack the malignant clone in an alternative manner. Therefore we used the combination of bortezomib, dexametasone and daily low dose of oral cyclophosphamide as an induction regimen followed by one year of maintenance therapy consisting of bortezomib and cyclophosphamide. Methods: Relapsing myeloma patients, bortezomib naïve, were treated with three cycles of 1.3 mg/m2 bortezomib at day 1, 4, 8 and 11, cyclophosphamide 50 mg daily, and 20 mg dexamethasone at day 1, 2, 4, 5, 8, 9, 11 and 12 followed by three cycles of bortezomib 1.6 mg/m2 (day 1, 8, 15 and 2), cyclophosphamide (50 mg) daily and dexamethasone (20 mg) at day 1, 2, 8, 9, 15, 16, 22 and 23. Maintenance therapy consisting of bortezomib 1.3 mg/m2 every two weeks and daily dose of 50 mg cyclophosphamide for one year was applied to patients in partial or complete remission. Primary endpoints were toxicity during re-induction and maintenance therapy. Secondary endpoints were response to treatment and progression free and overall survival. Results: 59 patients with relapsing multiple myeloma were included of whom 69% were in first relapse (Table 1). The upfront treatment consisted mainly of thalidomide-based and vincristine-based chemotherapy and 40% of the patients have been treated with an autologous stem cell transplantation. All 6 cycles of induction chemotherapy could be given in 49% of the patients. Premature discontinuation before starting maintenance therapy was due to toxicity (31%), progressive disease (7%), death (7%) or other reasons (6%). Myelosuppression was the most common side effect with WHO grade 3-4 in 31% of the patients. Neuropathy grade 3-4 was observed in 16% of patients, partially due to the fact that bortezomib was given intravenously during the first 2 yrs of the protocol which included 76% of the patients. Maintenance therapy was started in 47% of the patients with a median duration of 7.3 months (range 0.36.-13.4). Grade 3-4 toxicity was observed in 25% of the patients including infections (n=3) and myelosuppression (n=3) which did not resulted in discontinuation of therapy. Median follow up time was 29 months with an overall response of 62%, and a very good partial response (VGPR), complete remission (CR) in 21% and 7% of the patients respectively. During the maintenance phase an improvement in responsiveness was observed in 25% of the patients. The CR rate increased with 9% to a total of 16%. VGPR rate was 20% and 16% of the patient had a PR. At end of the maintenance therapy 50% of patients started with maintenance had stable disease. The median progression free survival (PFS) was 17.2 months (range 0.13 – 43.5) as depicted in figure 1. and the median overall survival was 21.6 months (range 0.46-54.4, figure 2). During follow up 33 % of the patients died due to progression of MM. Conclusion: The present study demonstrates that combination therapy with bortezomib, continuous low dose cyclophosphamide and dexamethasone is an effective and manageable regimen. Adding a year of maintenance was feasible with limited side effects and an increase in CR rate. Table 1: patient characteristics Patients (%) Age, mean (min,max) 69 (46-86) Sex Male 56 Female 44 Relapse number First relapse 75 Second relapse 20 Third relapse 5 Performance status 0 65 1 29 2 5 M-protein heavy chain IgA 18 IgG 65 Light chain disease 18 Polyneuropathy No 61 Yes 39 Figure 1: Progression free survival Figure 1:. Progression free survival Figure 2: Overall survival Figure 2:. Overall survival Disclosures Waal de: Jansen Cilag: Research Funding. Munck de:Jansen Cilag: Research Funding. Woolthuis:Jansen Cilag: Research Funding. velden Van Der:Jansen Cilag: Research Funding. Tromp:Jansen Cilag: Research Funding. Hoogendoorn:Jansen Cilag: Research Funding. Vellenga:Jansen Cilag: Research Funding. Hovenga:Jansen Cilag: Research Funding.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
水知寒完成签到,获得积分0
刚刚
柳亦诚发布了新的文献求助10
1秒前
molihuakai的应助被李佳佳采纳,获得10
2秒前
怕黑的缘分的应助被stone采纳,获得10
2秒前
余香的应助被saflgf采纳,获得10
2秒前
3秒前
粽粽发布了新的文献求助10
3秒前
侯_发布了新的文献求助30
3秒前
饼饼发布了新的文献求助10
4秒前
jiangjiang完成签到,获得积分10
4秒前
ylva发布了新的文献求助10
4秒前
秋风完成签到 ,获得积分10
4秒前
5秒前
羊咩咩发布了新的文献求助10
5秒前
英俊的小懒虫完成签到 ,获得积分10
5秒前
6秒前
香蕉八宝粥完成签到,获得积分10
6秒前
e00ec发布了新的文献求助10
6秒前
6秒前
与一人同游完成签到,获得积分10
6秒前
所所的应助被霁月采纳,获得10
6秒前
乐观自信热爱完成签到,获得积分10
6秒前
只争朝夕的应助被可妍昇采纳,获得10
7秒前
yang发布了新的文献求助10
7秒前
7秒前
zys完成签到,获得积分10
7秒前
7秒前
852的应助被ltttttt采纳,获得10
8秒前
英吉利25发布了新的文献求助20
8秒前
淡淡文博完成签到,获得积分10
8秒前
zz完成签到 ,获得积分10
8秒前
Lucas的应助被调皮钧采纳,获得10
9秒前
123完成签到,获得积分10
9秒前
酷炫不斜完成签到 ,获得积分10
9秒前
9秒前
三十六完成签到,获得积分20
9秒前
JamesPei的应助被1234567采纳,获得10
9秒前
张欣雨完成签到,获得积分10
9秒前
阿巴阿巴完成签到,获得积分10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180927
求助须知:如何正确求助?哪些是违规求助? 9570973
关于积分的说明 21815578
捐赠科研通 7777227
什么是DOI,文献DOI怎么找? 3433367
关于科研通互助平台的介绍 2557621
邀请新用户注册赠送积分活动 2479346